Neurosense Therapeutics is trading 5.46% lower at $3.46, with no confirmed catalyst identified in the sources reviewed.
- No company-specific announcement dated October 12 was located; the latest company news found was its October 2 Nasdaq listing-compliance update.
- The broader market was mixed, not sharply lower, and available biotech-sector coverage does not establish a same-day sector decline as the cause.